FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses
BIL also holds an option to increase its equity stake by an additional 15%
Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities
Relonchem receives marketing authorization for Moxonidine tablets
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
Encouraging early detection and breaking the silence around men’s health
Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem
Subscribe To Our Newsletter & Stay Updated